CD8A-Binding FN3 Domains for Noninvasive CD8+ T Cell Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods to monitor immune responses in tumors are limited by their inability to noninvasively and quantitatively assess changes in immune cell numbers and localization during immunotherapeutic interventions, which are crucial for understanding treatment efficacy.
Innovation Solution
Development of CD8A-binding fibronectin type III (FN3) domains that can be conjugated to detectable labels for noninvasive imaging and quantification of CD8+ T cells, utilizing polynucleotides and vectors to express these domains in various cells, and employing diagnostic agents like Zr-89 or I-124 for cancer diagnostics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to monitor immune responses, then existing diagnostic tools can be applied, but the ability to noninvasively and quantitatively assess changes in immune cell numbers and localization is limited
Solution Approach 1:
The patent employs fibronectin type III (FN3) domains as intermediary binding molecules that specifically recognize and bind to CD8A on the surface of CD8+ T cells. These FN3 domains are conjugated to detectable labels (such as radionuclides Zr-89 or I-124, fluorescent dyes, or magnetic particles) to serve as mediators between the target cells and imaging/detection systems, enabling noninvasive quantitative monitoring of immune cell distribution and dynamics in tumor microenvironments
Solution Approach 2:
The patent utilizes detectable labels with varying detection parameters (radioactivity, fluorescence intensity, magnetic signal strength) to quantify immune cell numbers and localization. By changing the detection parameter from qualitative to quantitative measurement, the system achieves precise assessment of immune cell dynamics during immunotherapeutic interventions
2Loss of information
If current diagnostic methods are used, then existing imaging and detection technologies can be applied, but the ability to monitor dynamic and spatial information of immune responses is insufficient
Solution Approach 1:
The patent segments the complex task of immune response monitoring into distinct functional components: (1) CD8A-specific binding via FN3 domains for target recognition, (2) detectable labels for signal generation, and (3) imaging/detection systems for data acquisition. This segmentation allows each component to be optimized independently while maintaining overall system functionality for capturing spatial and dynamic immune response information
Solution Approach 2:
The FN3 domain platform serves multiple functions: it provides specific binding to CD8A, enables conjugation to various detectable labels (radioactive, fluorescent, magnetic), and facilitates both in vitro and in vivo applications. This multi-functionality reduces the need for multiple different diagnostic tools, simplifying the overall system while maintaining comprehensive monitoring capabilities
3Reliability
If immunotherapies are administered to treat cancer, then treatment efficacy may be improved, but the ability to assess treatment efficacy through monitoring immune cell changes is limited
Solution Approach 1:
The patent enables real-time feedback monitoring of CD8+ T cell dynamics in tumor microenvironments during immunotherapeutic treatments. By quantitatively measuring changes in immune cell numbers and localization over time, clinicians can assess treatment efficacy and make informed decisions about continuing, modifying, or discontinuing immunotherapy regimens based on actual immune response data
Data Source
AI summary
Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.